...rights to resulting products. Further terms were not disclosed. Baxter International Inc. (BAX), Deerfield, Ill. GenOdyssee S.A....

...variants or with standard IFN alpha-2b. GEA007.1 is an antiviral interferon (IFN) alpha 17 variant. GenOdyssee S.A....

...to develop and commercialize a GenOdyssee compound. The compound will be selected from a predefined GenOdyssee...
...first development rights for all other indications and sole manufacturing rights for the licensed compound. GenOdyssee...
...Phase III trails, and a share of the out-licensing revenues. Debiopharm S.A. , Lausanne, Switzerland GenOdyssee S.A....

...to develop and commercialize a GenOdyssee compound. The compound will be selected from a predefined GenOdyssee...
...first development rights for all other indications and sole manufacturing rights for the licensed molecule. GenOdyssee...

...Although protein therapeutics have attained blockbuster status, GenOdyssee S.A. sees an opportunity to make many such therapies...
...a low dose would keep the same toxicity in humans but give higher efficacy." Because GenOdyssee...
...those methods because the proteins have never been in man before. To find improved proteins, GenOdyssee...

...and suggest that the IFN alpha variants are better tolerated than those on the market GenOdyssee...

...market nucleic acid analysis services performed by GenOdyssee in the U.S., EU, Switzerland and Japan. GenOdyssee S.A....